Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.19
+0.36 (1.39%)
At close: Aug 14, 2026, 4:00 PM EDT
25.88
-0.31 (-1.18%)
After-hours: Aug 14, 2026, 7:51 PM EDT
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $129.86M in the quarter ending June 30, 2026, with 59.33% growth. This brings the company's revenue in the last twelve months to $463.98M, up 76.11% year-over-year. In the year 2025, Arcutis Biotherapeutics had annual revenue of $376.07M with 91.34% growth.
Revenue (ttm)
$463.98M
Revenue Growth
+76.11%
P/S Ratio
7.09
Revenue / Employee
$1,310,681
Employees
354
Market Cap
3.29B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.07M | 179.53M | 91.34% |
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 606.33M |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| AbCellera Biologics | 66.17M |
| uniQure | 18.67M |
| Alumis | 7.40M |
| NewAmsterdam Pharma Company | 7.12M |
| Immunome | 4.02M |
ARQT News
- 7 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley - TheFly
- 9 days ago - Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho - TheFly
- 9 days ago - Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim - TheFly
- 9 days ago - Arcutis Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 9 days ago - Arcutis Biotherapeutics Earnings release: Q2 2026 - Filings
- 9 days ago - Arcutis Biotherapeutics Quarterly report: Q2 2026 - Filings
- 9 days ago - Arcutis Biotherapeutics Slides: Q2 2026 - Filings